Literature DB >> 17237497

Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.

Myat Lin Oo1, Shobha Thangada, Ming-Tao Wu, Catherine H Liu, Timothy L Macdonald, Kevin R Lynch, Chen-Yong Lin, Timothy Hla.   

Abstract

Sphingosine 1-phosphate (S1P), a multifunctional lipid mediator, regulates lymphocyte trafficking, vascular permeability, and angiogenesis by activation of the S1P1 receptor. This receptor is activated by FTY720-P, a phosphorylated derivative of the immunosuppressant and vasoactive compound FTY720. However, in contrast to the natural ligand S1P, FTY720-P appears to act as a functional antagonist, even though the mechanisms involved are poorly understood. In this study, we investigated the fate of endogenously expressed S1P1 receptor in agonist-activated human umbilical vein endothelial cells and human embryonic kidney 293 cells expressing green fluorescent protein-tagged S1P1. We show that FTY720-P is more potent than S1P at inducing receptor degradation. Pretreatment with an antagonist of S1P1, VPC 44116, prevented receptor internalization and degradation. FTY720-P did not induce degradation of internalization-deficient S1P1 receptor mutants. Further, small interfering RNA-mediated down-regulation of G protein-coupled receptor kinase-2 and beta-arrestins abolished FTY720-P-induced S1P1 receptor degradation. These data suggest that agonist-induced phosphorylation of S1P1 and subsequent endocytosis are required for FTY720-P-induced degradation of the receptor. S1P1 degradation is blocked by MG132, a proteasomal inhibitor. Indeed, FTY720-P strongly induced polyubiquitinylation of S1P1 receptor, whereas S1P at concentrations that induced complete internalization was not as efficient, suggesting that receptor internalization is required but not sufficient for ubiquitinylation and degradation. We propose that the ability of FTY720-P to target the S1P1 receptor to the ubiquitinylation and proteasomal degradation pathway may at least in part underlie its immunosuppressive and anti-angiogenic properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237497     DOI: 10.1074/jbc.M610318200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  169 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  Ubiquitination of G protein-coupled receptors: functional implications and drug discovery.

Authors:  Michael R Dores; JoAnn Trejo
Journal:  Mol Pharmacol       Date:  2012-06-14       Impact factor: 4.436

Review 3.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

Review 5.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

Review 6.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 7.  G protein-coupled receptor sorting to endosomes and lysosomes.

Authors:  Adriano Marchese; May M Paing; Brenda R S Temple; JoAnn Trejo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

8.  Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation.

Authors:  Hsing-Chuan Tsai; Yingxiang Huang; Christopher S Garris; Monica A Moreno; Christina W Griffin; May H Han
Journal:  JCI Insight       Date:  2016-06-16

9.  Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.

Authors:  Luke M Healy; Graham K Sheridan; Adam J Pritchard; Aleksandra Rutkowska; Florian Mullershausen; Kumlesh K Dev
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  Sphingosine 1-phosphate-regulated transcriptomes in heterogenous arterial and lymphatic endothelium of the aorta.

Authors:  Eric Engelbrecht; Michel V Levesque; Liqun He; Michael Vanlandewijck; Anja Nitzsche; Hira Niazi; Andrew Kuo; Sasha A Singh; Masanori Aikawa; Kristina Holton; Richard L Proia; Mari Kono; William T Pu; Eric Camerer; Christer Betsholtz; Timothy Hla
Journal:  Elife       Date:  2020-02-24       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.